Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01951586 · ClinicalTrials.gov registry record · Phase 2
Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer
A Phase 2 study, sponsored by Amgen.
- Completed
- Registry status
- Phase 2
- Development phase
- 226
- Enrollment target
NCT01951586 is a Phase 2 study that has completed, run by Amgen. The registered enrollment target is 226 participants.
The verdict
NCT01951586, a Phase 2 study, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 226 participants
- Enrollment target
Study Summary
This randomized phase 2 trial is studying the effect of adding denosumab to standard chemotherapy in the treatment of advanced lung cancer.
Interventions
- DRUG Zoledronic acid
- DRUG Denosumab
- DRUG Standard Chemotherapy
- DRUG Placebo to Denosumab
- DRUG Placebo to Zoledronic Acid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 226 participants |
| Start Date | 2013-12-31 |
| Est. Completion | 2017-11-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01951586
The ClinicalTrials.gov registry entry for NCT01951586 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 226 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Zoledronic acid is the first listed.
NCT01951586 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01951586 about?
NCT01951586 is a clinical study titled "Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer". This randomized phase 2 trial is studying the effect of adding denosumab to standard chemotherapy in the treatment of advanced lung cancer.
What is the current status of trial NCT01951586?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 226 participants. The study started on 2013-12-31. Estimated completion is 2017-11-28.
What interventions are being tested in trial NCT01951586?
The interventions under investigation include: Zoledronic acid (DRUG), Denosumab (DRUG), Standard Chemotherapy (DRUG), Placebo to Denosumab (DRUG), Placebo to Zoledronic Acid (DRUG).
Who is sponsoring clinical trial NCT01951586?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.